| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Tea Blom,1,
José Antonio Bengoechea,5
Camino Pérez-Gutiérrez,5
Peter Ahrens,4,
and
Jeffrey Hoorfar3
Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki,1 Helsinki University Central Hospital Laboratory Diagnostics, Helsinki, Finland,2 National Food Institute,3 National Veterinary Institute, Technical University of Denmark, Copenhagen, Denmark,4 Unidad de Investigacion, Hospital Son Dureta, Palma Mallorca, and Program Infection and Immunity, Fundación Caubet-Cimera Illes Balears, Bunyola, Spain5
Received 19 April 2007/ Accepted 16 July 2007
Yersinia enterocolitica serotype O:9 is a gram-negative enteropathogen that infects animals and humans. The role of lipopolysaccharide (LPS) in Y. enterocolitica O:9 pathogenesis, however, remains unclear. The O:9 LPS consists of lipid A to which is linked the inner core oligosaccharide, serving as an attachment site for both the outer core (OC) hexasaccharide and the O-polysaccharide (OPS; a homopolymer of N-formylperosamine). In this work, we cloned the OPS gene cluster of O:9 and identified 12 genes organized into four operons upstream of the gnd gene. Ten genes were predicted to encode glycosyltransferases, the ATP-binding cassette polysaccharide translocators, or enzymes required for the biosynthesis of GDP-N-formylperosamine. The two remaining genes within the OPS gene cluster, galF and galU, were not ascribed a clear function in OPS biosynthesis; however, the latter gene appeared to be essential for O:9. The biological functions of O:9 OPS and OC were studied using isogenic mutants lacking one or both of these LPS parts. We showed that OPS and OC confer resistance to human complement and polymyxin B; the OPS effect on polymyxin B resistance could be observed only in the absence of OC.
Published ahead of print on 10 August 2007.
Present address: Bio Science and Technology, BioCentrum, Technical University of Denmark, Copenhagen, Denmark.
Present address: Molecular Cancer Biology Program, 00014 University of Helsinki, Finland.
Present address: Statens Serum Institut, Copenhagen, Denmark.
This article has been cited by other articles:
| Appl. Environ. Microbiol. | Infect. Immun. | Eukaryot. Cell |
|---|---|---|
| Mol. Cell. Biol. | J. Virol. | Microbiol. Mol. Biol. Rev. |
| ALL ASM JOURNALS |